๐ฐ Accessed August News
Page 7 - Accessed August News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Accessed August. Real-time updates on events, politics, business and more.
September 22, 2023
Safety planning by peers is feasible and acceptable to patients, might result in decreased ED visits, and may represent a way of implementing safety plans in rural EDs.
September 20, 2023
There is an urgent need to implement proactive measures so the future population can enjoy a healthy, safe, and sustainable existence. There is a need to establish sustainable processes before the population reaches numbers that exceed what current infrastructure can maintain.
September 19, 2023
Results from a retrospective cohort study from 2015 to 2020 demonstrated a notable rise with increasing age in pneumonia-related medical encounters following...
September 19, 2023
An estimated 31% of physicians have been sued at some point in their careers. Here's what you need to know.
September 18, 2023
How can we ensure that diversity, equity, inclusion, and access are truly achieved in clinical trials industry-wide?
September 15, 2023
Osmotic power is a form of renewable energy that experts have predicted could have the potential to produce half of Europeโs power by 2030. French energy supplier Sweetch is exploring new ways of producing renewable energy via osmotic power to address carbon emissions associated with our reliance on non-renewable fossil fuels.
September 14, 2023
The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.
September 14, 2023
Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed August 2023. European Society...
September 11, 2023
Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...
September 11, 2023
Daiichi Sankyo and AstraZenecaโs ENHERTU showed objective response rates of 49% and 56% with 5.4 mg/kg and 6.4 mg/kg doses, respectively, in primary analysis ENHERTU provided a median...